Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies

Human Antibodies

Volumn 18, Issue 3, 2009, Pages 47-73

  Damen, Carola W N ^a   Schellens, Jan H M ^b,c   Beijnen, Jos H ^a,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Bioanalysis; ELISA; Immunoassay; LC MS MS; Monoclonal antibody; Quantification

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ALPHA4 INTEGRIN; ATLIZUMAB; BASILIXIMAB; BEVACIZUMAB; CD20 ANTIGEN; CD3 ANTIGEN; CD52 ANTIGEN; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IBRITUMOMAB TIUXETAN; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RITUXIMAB; ROACTEMRA; STELARA; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB; VASCULOTROPIN;

ALLERGIC ASTHMA; ANKYLOSING SPONDYLITIS; B CELL LEUKEMIA; B CELL LYMPHOMA; BINDING ASSAY; BREAST CANCER; CARDIAC GRAFT REJECTION; CHEMOLUMINESCENCE; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CROHN DISEASE; DOSIMETRY; DRUG DETERMINATION; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; LIGAND BINDING; LIQUID CHROMATOGRAPHY; LIVER GRAFT REJECTION; LUNG NON SMALL CELL CANCER; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TANDEM MASS SPECTROMETRY; ULCERATIVE COLITIS; VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYMES; HUMANS; IMMUNOASSAY; LIGANDS; RADIOMETRY; RADIOPHARMACEUTICALS; SPECTROMETRY, FLUORESCENCE;

EID: 70349150974     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/HAB-2009-0206     Document Type: Review

References (208)

1. C. Piggee, Therapeutic antibodies coming through the pipeline, Anal Chem 80 (2008), 2305-2310.
2. M.A. Mascelli, H. Zhou, R. Sweet, J. Getsy, H.M. Davis, M. Graham and D. Abernethy, Molecular, biologic, and phar-macokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development, J Clin Phar-macol 47 (2007), 553-565.
3. H. Blasco, G. Lalmanach, E. Godat, M.C. Maurel, S. Canepa, M. Belghazi, G. Paintaud, D. Degenne, E. Chatelut, G. Cartron and C. Le Guellec, Evaluation of a peptide ELISA for the detection of rituximab in serum, J Immunol Methods 325 (2007), 127-139.
4. US Food and Drug Administration: Centre for Drug Evaluation and Research, Guidance for Industry: Bioanalytical Method Validation, Available: www.fdagov/cder/guidance/4252fnl.htm (2001).
5. B. DeSilva, W. Smith, R. Weiner, M. Kelley, J. Smolec, B. Lee, M. Khan, R. Tacey, H. Hill and A. Celniker, Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules, Pharm Res 20 (2003), 1885-1900.
6. K.J. Miller, R.R. Bowsher, A. Celniker, J. Gibbons, S. Gup-ta, J.W. Lee, S.J. Swanson, W.C. Smith and R.S. Weiner, Workshop on bioanalytical methods validation for macromolecules: summary report, Pharm Res 18 (2001), 1373-1383.
7. J. Smolec, B. DeSilva, W. Smith, R. Weiner, M. Kelly, B. Lee, M. Khan, R. Tacey, H. Hill, A. Celniker, V. Shah, R. Bow-sher, A. Mire-Sluis, J.W. Findlay, M. Saltarelli, V. Quarm-by, D. Lansky, R. Dillard, M. Ullmann, S. Keller and H.T. Karnes, Bioanalytical method validation for macromolecules in support of pharmacokinetic studies, Pharm Res 22 (2005), 1425-1431.
8. M. Kelley and B. DeSilva, Key elements of bioanalytical method validation for macromolecules, AAPS J 9 (2007), E156-E163.
9. C.T. Viswanathan, S. Bansal, B. Booth, A.J. DeStefano, M.J. Rose, J. Sailstad, V.P. Shah, J.P. Skelly, P.G. Swann and R. Weiner, Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and lig-and binding assays, Pharm Res 24 (2007), 1962-1973. (Pubitemid 47389236)
10. I. Jilani, M. Keating, F.J. Giles, S. O'Brien, H.M. Kantarjian and M. Albitar, Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay, Leuk Res 28 (2004), 1255-1262.
11. M. Montagna, M.A. Avanzini, L. Visai, F. Locatelli, M. Mon-tillo, E. Morra and M.B. Regazzi, A new sensitive enzyme-linked immunosorbent assay (ELISA) for Alemtuzumab determination: development, validation and application, Int J Immunopathol Pharmacol 20 (2007), 363-371.
12. P. Rebello and G. Hale, Pharmacokinetics of CAMPATH-1H: assay development and validation, J Immunol Methods 260 (2002), 285-302.
13. B.E. Fayer, P.P. Soni, M.H. Binger, D.R. Mould and H. Satoh, Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay, J Immunol Methods 186 (1995), 47-54.
14. D. Ternant, D. Mulleman, D. Degenne, S. Willot, J.M. Guil-laumin, H. Watier, P. Goupille and G. Paintaud, An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab, Ther Drug Monit 28 (2006), 169-174.
15. P.V. Beum, A.D. Kennedy and R.P. Taylor, Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas, J Immunol Methods 289 (2004), 97-109.
16. I. Iacona, M. Lazzarino, M.A. Avanzini, M. Rupolo, L. Ar-caini, C. Astori, F. Lunghi, E. Orlandi, E. Morra, V. Zagonel and M.B. Regazzi, Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study, Ther Drug Monit 22 (2000), 295-301.
17. C.W. Damen, E.R. de Groot, M. Heij, D.S. Boss, J.H. Schel-lens, H. Rosing, J.H. Beijnen and L.A. Aarden, Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma, Anal Biochem 391 (2009), 114-120.
18. L. Maple, R. Lathrop, S. Bozich, W. Harman, R. Tacey, M. Kelley and A. Danilkovitch-Miagkova, Development and validation of ELISA for herceptin detection in human serum, J Immunol Methods 295 (2004), 169-182.
19. I. Nestorov, Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34 (2005), 12-18.
20. I. Nestorov, Clinical pharmacokinetics of tumor necrosis factor antagonists, J Rheumatol Suppl 74 (2005), 13-18. (Pubitemid 40365775)
21. A. den Broeder, P.L. van de, R. Rau, M. Schattenkirchner, P. Van Riel, O. Sander, C. Binder, H. Fenner, Y. Bankmann, R. Velagapudi, J. Kempeni and H. Kupper, A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis, J Rheumatol 29 (2002), 2288-2298.
22. M.H. Weisman, L.W. Moreland, D.E. Furst, M.E. Weinblatt, E.C. Keystone, H.E. Paulus, L.S. Teoh, R.B. Velagapudi, P.A. Noertersheuser, G.R. Granneman, S.A. Fischkoff and E.K. Chartash, Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study, Clin Ther 25 (2003), 1700-1721.
23. A.E. van der Bijl, F.C. Breedveld, C.E. Antoni, J.R. Kalden, S. Kary, G.R. Burmester, C. Beckmann, K. Unnebrink and H. Kupper, An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status, Clin Rheumatol 27 (2008), 1021-1028.
24. G.M. Bartelds, C.A. Wijbrandts, M.T. Nurmohamed, S. Stapel, W.F. Lems, L. Aarden, B.A. Dijkmans, P.P. Tak and G.J. Wolbink, Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis, Ann Rheum Dis 66 (2007), 921-926.
25. J.D. Isaacs, V.K. Manna, N. Rapson, K.J. Bulpitt, B.L. Ha-zleman, E.L. Matteson, E.W. St Clair, T.J. Schnitzer and J.M. Johnston, CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study, Br J Rheumatol 35 (1996), 231-240.
26. H.E. Chan, I. Jilani, R. Chang and M. Albitar, Measuring humanized antibodies in plasma of patients treated with antibody-based therapy using bead-based flow cytometry: the story of alemtuzumab, Methods Mol Biol 378 (2007), 159-165.
27. P.L. Amlot, E. Rawlings, O.N. Fernando, P.J. Griffin, G. Heinrich, M.H. Schreier, J.P. Castaigne, R. Moore and P. Sweny, Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation, Transplantation 60 (1995), 748-756.
28. J.M. Kovarik, P. Wolf, J.M. Cisterne, G. Mourad, Y. Le-branchu, P. Lang, B. Bourbigot, D. Cantarovich, D. Girault, C. Gerbeau, A.G. Schmidt and J.P. Soulillou, Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts, Transplantation 64 (1997), 1701-1705.
29. J.M. Kovarik, T. Breidenbach, C. Gerbeau, A. Korn, A.G. Schmidt and B. Nashan, Disposition and immunodynamics of basiliximab in liver allograft recipients, Clin Pharmacol Ther 64 (1998), 66-72.
30. S. Michels, U. Schmidt-Erfurth and P.J. Rosenfeld, Promising new treatments for neovascular age-related macular degeneration, Expert Opin Investig Drugs 15 (2006), 779-793.
31. S.J. Bakri, M.R. Snyder, J.M. Reid, J.S. Pulido and R.J. Singh, Pharmacokinetics of intravitreal bevacizumab (Avastin), Ophthalmology 114 (2007), 855-859.
32. E. Yoeruek, F. Ziemssen, S. Henke-Fahle, O. Tatar, A. Tu-ra, S. Grisanti, K.U. Bartz-Schmidt and P. Szurman, Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn, Acta Ophthalmol 86 (2008), 322-328.
33. S.J. Bakri, M.R. Snyder, J.S. Pulido, C.A. McCannel, W.T. Weiss and R.J. Singh, Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing, Retina 26 (2006), 519-522.
34. Q. Zhu, F. Ziemssen, S. Henke-Fahle, O. Tatar, P. Szurman, S. Aisenbrey, N. Schneiderhan-Marra, X. Xu and S. Grisan-ti, Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovasculariza-tion, Ophthalmology 115 (2008), 1750-5, 1755.
35. P.M. Beer, S.J. Wong, A.M. Hammad, N.S. Falk, M.R. O'Malley and S. Khan, Vitreous levels of unbound beva-cizumab and unbound vascular endothelial growth factor in two patients, Retina 26 (2006), 871-876.
36. F.R. Luo, Z. Yang, H. Dong, A. Camuso, K. McGlinchey, K. Fager, C. Flefleh, D. Kan, I. Inigo, S. Castaneda, W.C. Rose, R.A. Kramer, R. Wild and F.Y. Lee, Correlation of pharma-cokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft, Cancer Chemother Pharmacol 56 (2005), 455-464.
37. J. Baselga, D. Pfister, M.R. Cooper, R. Cohen, B. Burtness, M. Bos, G. D'Andrea, A. Seidman, L. Norton, K. Gunnett, J. Falcey, V. Anderson, H. Waksal and J. Mendelsohn, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin, J Clin Oncol 18 (2000), 904-914.
38. F. Robert, M.P. Ezekiel, S.A. Spencer, R.F. Meredith, J.A. Bonner, M.B. Khazaeli, M.N. Saleh, D. Carey, A.F. LoBuglio, R.H. Wheeler, M.R. Cooper and H.W. Waksal, Phase I study of anti - epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer, J Clin Oncol 19 (2001), 3234-3243.
39. R. Hirose, J.P. Roberts, D. Quan, R.W. Osorio, C. Freise, N.L. Ascher and P.G. Stock, Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation, Transplantation 69 (2000), 307-311.
40. M. Koch, G. Niemeyer, I. Patel, S. Light and B. Nashan, Phar-macokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation, Transplantation 73 (2002), 1640-1646. (Pubitemid 34568679)
41. R.B. Nussenblatt, D.J. Thompson, Z. Li, C.C. Chan, J.S. Peterson, R.R. Robinson, R.S. Shames, S. Nagarajan, M.T. Tang, M. Mailman, G. Velez, C. Roy, G.A. Levy-Clarke, E.B. Suhler, A. Djalilian, H.N. Sen, S. Al Khatib, R. Ursea, S. Srivastava, A. Bamji, S. Mellow, P. Sran, T.A. Waldmann and R.R. Buggage, Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration, J Autoimmun 21 (2003), 283-293.
42. M.D. Pescovitz, G. Bumgardner, R.S. Gaston, R.L. Kirkman, S. Light, I.H. Patel, K. Nieforth and F. Vincenti, Pharmacoki-netics of daclizumab and mycophenolate mofetil with cy-closporine and steroids in renal transplantation, Clin Transplant 17 (2003), 511-517. (Pubitemid 37461428)
43. M.D. Pescovitz, S. Knechtle, S.R. Alexander, P. Colombani, T. Nevins, K. Nieforth and M.R. Bouw, Safety and pharma-cokinetics of daclizumab in pediatric renal transplant recipients, Pediatr Transplant 12 (2008), 447-455.
44. F. Vincenti, M. Lantz, J. Birnbaum, M. Garovoy, D. Mould, J. Hakimi, K. Nieforth and S. Light, A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation, Transplantation 63 (1997), 33-38.
45. F. Vincenti, R. Kirkman, S. Light, G. Bumgardner, M. Pescovitz, P. Halloran, J. Neylan, A. Wilkinson, H. Ek-berg, R. Gaston, L. Backman and J. Burdick, Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group, N Engl J Med 338 (1998), 161-165.
46. F. Vincenti, D. Pace, J. Birnbaum and M. Lantz, Pharma-cokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation, Am J Transplant 3 (2003), 50-52.
47. W.K. Washburn, L.W. Teperman, T.G. Heffron, D.D. Douglas, S. Gay, E. Katz and G.B. Klintmalm, A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study, Liver Transpl 12 (2006), 585-591.
48. L. Charneski and P.N. Patel, Eculizumab in paroxysmal nocturnal haemoglobinuria, Drugs 68 (2008), 1341-1346.
49. T.C. Thomas, S.A. Rollins, R.P. Rother, M.A. Giannoni, S.L. Hartman, E.A. Elliott, S.H. Nye, L.A. Matis, S.P. Squinto and M.J. Evans, Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv, Mol Immunol 33 (1996), 1389-1401.
50. A. Hill, P. Hillmen, S.J. Richards, D. Elebute, J.C. Marsh, J. Chan, C.F. Mojcik and R.P. Rother, Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria, Blood 106 (2005), 2559-2565.
51. P. Hillmen, C. Hall, J.C. Marsh, M. Elebute, M.P. Bombara, B.E. Petro, M.J. Cullen, S.J. Richards, S.A. Rollins, C.F. Mojcik and R.P. Rother, Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria, N Engl J Med 350 (2004), 552-559.
52. R.J. Bauer, R.L. Dedrick, M.L. White, M.J. Murray and M.R. Garovoy, Population pharmacokinetics and pharmaco-dynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis, J Pharmacokinet Biopharm 27 (1999), 397-420.
53. D.L. Mortensen, P.A. Walicke, X. Wang, P. Kwon, P. Kue-bler, A.B. Gottlieb, J.G. Krueger, C. Leonardi, B. Miller and A. Joshi, Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis, J Clin Pharmacol 45 (2005), 286-298.
54. Y.N. Sun, J.F. Lu, A. Joshi, P. Compton, P. Kwon and R.A. Bruno, Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects, J Clin Pharmacol 45 (2005), 468-476.
55. A.B. Gottlieb, J.G. Krueger, K. Wittkowski, R. Dedrick, P.A. Walicke and M. Garovoy, Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody, Arch Dermatol 138 (2002), 591-600.
56. A.B. Gottlieb, B. Miller, N. Lowe, W. Shapiro, C. Hudson, R. Bright, M. Ling, A. Magee, C.O. McCall, T. Rist, W. Dummer, P. Walicke, R.J. Bauer, M. White and M. Garovoy, Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis, J Cutan Med Surg 7 (2003), 198-207.
57. C.M. Ng, A. Joshi, R.L. Dedrick, M.R. Garovoy and R.J. Bauer, Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis, Pharm Res 22 (2005), 1088-1100.
58. K. Papp, R. Bissonnette, J.G. Krueger, W. Carey, D. Gratton, W.P. Gulliver, H. Lui, C.W. Lynde, A. Magee, D. Minier, J.P. Ouellet, P. Patel, J. Shapiro, N.H. Shear, S. Kramer, P. Walicke, R. Bauer, R.L. Dedrick, S.S. Kim, M. White and M.R. Garovoy, The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody, J Am Acad Dermatol 45 (2001), 665-674.
59. D. Dayde, D. Ternant, M. Ohresser, S. Lerondel, S. Pes-nel, H. Watier, A. Le Pape, P. Bardos, G. Paintaud and G. Cartron, Tumor burden influences exposure and response to rituximab: pharmacokinetic - pharmacodynamic modelling using a syngeneic bioluminescent murine model expressing human CD20, Blood 113 (2009), 3765-3772.
60. D. Ternant, A. Aubourg, C. Magdelaine-Beuzelin, D. De-genne, H. Watier, L. Picon and G. Paintaud, Infliximab phar-macokinetics in inflammatory bowel disease patients, Ther Drug Monit 30 (2008), 523-529.
61. G. Van Assche, C. Magdelaine-Beuzelin, G. D'Haens, F. Baert, M. Noman, S. Vermeire, D. Ternant, H. Watier, G. Paintaud and P. Rutgeerts, Withdrawal of immunosup-pression in Crohn's disease treated with scheduled inflix-imab maintenance: a randomized trial, Gastroenterology 134 (2008), 1861-1868.
62. G.J. Wolbink, A.E. Voskuyl, W.F. Lems, E. de Groot, M.T. Nurmohamed, P.P. Tak, B.A. Dijkmans and L. Aarden, Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to in-fliximab treatment in patients with rheumatoid arthritis, Ann Rheum Dis 64 (2005), 704-707.
63. M.K. de Vries, G.J. Wolbink, S.O. Stapel, H. de Vrieze, J.C. van Denderen, B.A. Dijkmans, L.A. Aarden and van der Horst-Bruinsma IE, Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation, Ann Rheum Dis 66 (2007), 1252-1254.
64. R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, J.D. Macfarlane, C. Antoni, B. Leeb, M.J. Elliott, J.N. Woody, T.F. Schaible and M. Feldmann, Therapeutic effica-cy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis Rheum 41 (1998), 1552-1563.
65. A. Kavanaugh, E.W. St Clair, W.J. McCune, T. Braakman and P. Lipsky, Chimeric anti-tumor necrosis factor-alpha mono-clonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy, J Rheumatol 27 (2000), 841-850.
66. Z. Xu, K. Seitz, A. Fasanmade, J. Ford, P. Williamson, W. Xu, H.M. Davis and H. Zhou, Population pharmacokinetics of infliximab in patients with ankylosing spondylitis, J Clin Pharmacol 48 (2008), 681-695.
67. G.J. Zlabinger, W. Ulrich, A. Sonnleitner, E. Pohanka, O. Traindl and J. Kovarik, Determination of serum OKT3 levels with flow cytometry, Transplant Proc 21 (1989), 989-991.
68. E.S. Woodle, D.S. Bruce, M. Josephson, D. Cronin, K.A. Newell, J.M. Millis, J.B. Piper, R. O'Laughlin and J.R. Thistlethwaite, Jr., OKT3 escalating dose regimens provide effective therapy for renal allograft rejection, Clin Transplant 10 (1996), 389-395.
69. W.A. Sheremata, T.L. Vollmer, L.A. Stone, A.J. Willmer-Hulme and M. Koller, A safety and pharmacokinetic study of intravenous natalizumab in patients with MS, Neurology 52 (1999), 1072-1074.
70. T.L. Vollmer, J.T. Phillips, A.D. Goodman, M.A. Agius, M.A. Libonati, J.L. Giacchino and J.S. Grundy, An open-label safety and drug interaction study of natalizumab (An-tegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis, Mult Scler 10 (2004), 511-520.
71. B.O. Khatri, S. Man, G. Giovannoni, A.P. Koo, J.C. Lee, B. Tucky, F. Lynn, S. Jurgensen, J. Woodworth, S. Goelz, P.W. Duda, M.A. Panzara, R.M. Ransohoff and R.J. Fox, Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function, Neurology 72 (2009), 402-409.
72. F.H. Gordon, M.I. Hamilton, S. Donoghue, C. Greenlees, T. Palmer, D. Rowley-Jones, A.P. Dhillon, P.L. Amlot and R.E. Pounder, A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin, Aliment Pharmacol Ther 16 (2002), 699-705.
73. F.H. Gordon, C.W. Lai, M.I. Hamilton, M.C. Allison, E.D. Srivastava, M.G. Fouweather, S. Donoghue, C. Greenlees, J. Subhani, P.L. Amlot and R.E. Pounder, A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease, Gastroenterology 121 (2001), 268-274.
74. J.S. Hyams, D.C. Wilson, A. Thomas, R. Heuschkel, S. Mit-ton, B. Mitchell, R. Daniels, M.A. Libonati, S. Zanker and S. Kugathasan, Natalizumab therapy for moderate to severe Crohn disease in adolescents, J Pediatr Gastroenterol Nutr 44 (2007), 185-191.
75. D.H. Miller, O.A. Khan, W.A. Sheremata, L.D. Blumhardt, G.P. Rice, M.A. Libonati, A.J. Willmer-Hulme, C.M. Dalton, K.A. Miszkiel and P.W. O'Connor, A controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med 348 (2003), 15-23.
76. P.W. O'Connor, A. Goodman, A.J. Willmer-Hulme, M.A. Li-bonati, L. Metz, R.S. Murray, W.A. Sheremata, T.L. Vollmer and L.A. Stone, Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects, Neurology 62 (2004), 2038-2043.
77. B.E. Sands, R. Kozarek, J. Spainhour, C.F. Barish, S. Becker, L. Goldberg, S. Katz, R. Goldblum, R. Harrigan, D. Hilton and S.B. Hanauer, Safety and tolerability of concurrent na-talizumab treatment for patients with Crohn's disease not in remission while receiving infliximab, Inflamm Bowel Dis 13 (2007), 2-11.
78. N. Hayashi, Y. Tsukamoto, W.M. Sallas and P.J. Lowe, A mechanism-based binding model for the population pharma-cokinetics and pharmacodynamics of omalizumab, Br J Clin Pharmacol 63 (2007), 548-561.
79. R.G. Slavin, C. Ferioli, S.J. Tannenbaum, C. Martin, M. Blogg and P.J. Lowe, Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations, J Allergy Clin Immunol 123 (2009), 107-113.
80. T.B. Casale, I.L. Bernstein, W.W. Busse, C.F. LaForce, D.G. Tinkelman, R.R. Stoltz, R.J. Dockhorn, J. Reimann, J.Q. Su, R.B. Fick, Jr. and D.C. Adelman, Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis, J Allergy Clin Immunol 100 (1997), 110-121.
81. K.N. Subramanian, L.E. Weisman, T. Rhodes, R. Ariagno, P.J. Sanchez, J. Steichen, L.B. Givner, T.L. Jennings, F.H. Top, Jr., D. Carlin and E. Connor, Safety, tolerance and phar-macokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group, Pe-diatr Infect Dis J 17 (1998), 110-115. (Pubitemid 28096007)
82. Anonymous and The IMpact-RSV Study Group, Palivizum-ab, a humanized respiratory syncytial virus monoclonal anti-body, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group, Pediatrics 102 (1998), 531-537.
83. X. Saez-Llorens, E. Castano, D. Null, J. Steichen, P.J. Sanchez, O. Ramilo, F.H. Top, Jr. and E. Connor, Safety and pharmacokinetics of an intramuscular humanized monoclon-al antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group, Pediatr Infect Dis J 17 (1998), 787-791. (Pubitemid 28475545)
84. X. Saez-Llorens, M.T. Moreno, O. Ramilo, P.J. Sanchez, F.H. Top, Jr. and E.M. Connor, Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection, Pediatr Infect Dis J 23 (2004), 707-712.
85. M. Boeckh, M.M. Berrey, R.A. Bowden, S.W. Crawford, J. Balsley and L. Corey, Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants, J Infect Dis 184 (2001), 350-354.
86. S.Y. Wu, J. Bonaparte and S. Pyati, Palivizumab use in very premature infants in the neonatal intensive care unit, Pediatrics 114 (2004), e554-e556.
87. E.K. Rowinsky, G.H. Schwartz, J.A. Gollob, J.A. Thompson, N.J. Vogelzang, R. Figlin, R. Bukowski, N. Haas, P. Lockbaum, Y.P. Li, R. Arends, K.A. Foon, G. Schwab and J. Dutcher, Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer, J Clin Oncol 22 (2004), 3003-3015.
88. J.R. Hecht, A. Patnaik, J. Berlin, A. Venook, I. Malik, S. Tchekmedyian, L. Navale, R.G. Amado and N.J. Meropol, Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer, Cancer 110 (2007), 980-988. (Pubitemid 47312862)
89. L.M. Weiner, A.S. Belldegrun, J. Crawford, A.W. Tolcher, P. Lockbaum, R.H. Arends, L. Navale, R.G. Amado, G. Schwab and R.A. Figlin, Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies, Clin Cancer Res 14 (2008), 502-508.
90. N.L. Berinstein, A.J. Grillo-Lopez, C.A. White, I. Bence-Bruckler, D. Maloney, M. Czuczman, D. Green, J. Rosenberg, P. McLaughlin and D. Shen, Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, Ann Oncol 9 (1998), 995-1001.
91. D.G. Maloney, A.J. Grillo-Lopez, D.J. Bodkin, C.A. White, T.M. Liles, I. Royston, C. Varns, J. Rosenberg and R. Levy, IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma, J Clin Oncol 15 (1997), 3266-3274. (Pubitemid 27419340)
92. D.G. Maloney, A.J. Grillo-Lopez, C.A. White, D. Bodkin, R.J. Schilder, J.A. Neidhart, N. Janakiraman, K.A. Foon, T.M. Liles, B.K. Dallaire, K. Wey, I. Royston, T. Davis and R. Levy, IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood 90 (1997), 2188-2195.
93. J. Mangel, R. Buckstein, K. Imrie, D. Spaner, E. Franssen, P. Pavlin, A. Boudreau, N. Pennell, D. Combs and N.L. Berinstein, Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autolo-gous stem cell transplantation, Ann Oncol 14 (2003), 758-765.
94. P. McLaughlin, A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, M.E. Williams, M.R. Heyman, I. Bence-Bruckler, C.A. White, F. Cabanillas, V. Jain, A.D. Ho, J. Lis-ter, K. Wey, D. Shen and B.K. Dallaire, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol 16 (1998), 2825-2833.
95. L.N. Gordan, W.B. Grow, A. Pusateri, V. Douglas, N.P. Mendenhall and J.W. Lynch, Phase II trial of individualized rituximab dosing for patients with CD20-positive lympho-proliferative disorders, J Clin Oncol 23 (2005), 1096-1102.
96. J.L. Rubenstein, J. Fridlyand, L. Abrey, A. Shen, J. Karch, E. Wang, S. Issa, L. Damon, M. Prados, M. McDermott, J. O'Brien, C. Haqq and M. Shuman, Phase I study of intraven-tricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma, J Clin Oncol 25 (2007), 1350-1356.
97. J.L. Rubenstein, D. Combs, J. Rosenberg, A. Levy, M. McDermott, L. Damon, R. Ignoffo, K. Aldape, A. Shen, D. Lee, A. Grillo-Lopez and M.A. Shuman, Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment, Blood 101 (2003), 466-468.
98. A. Harjunpaa, T. Wiklund, J. Collan, R. Janes, J. Rosenberg, D. Lee, A. Grillo-Lopez and S. Meri, Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma, Leuk Lymphoma 42 (2001), 731-738.
99. C.M. Ng, R. Bruno, D. Combs and B. Davies, Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial, J Clin Pharmacol 45 (2005), 792-801.
100. H. Kim, K.G. Csaky, C.C. Chan, P.M. Bungay, R.J. Lutz, R.L. Dedrick, P. Yuan, J. Rosenberg, A.J. Grillo-Lopez, W.H. Wilson and M.R. Robinson, The pharmacokinetics of rit-uximab following an intravitreal injection, Exp Eye Res 82 (2006), 760-766.
101. N. Nishimoto, K. Yoshizaki, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, J. Hashimoto, J. Azuma and T. Kishimo-to, Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial, Arthritis Rheum 50 (2004), 1761-1769.
102. N. Nishimoto, K. Yoshizaki, K. Maeda, T. Kuritani, H. Deguchi, B. Sato, N. Imai, M. Suemura, T. Kakehi, N. Tak-agi and T. Kishimoto, Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study, J Rheumatol 30 (2003), 1426-1435.
103. M.D. Pegram, S. Hsu, G. Lewis, R. Pietras, M. Beryt, M. Sliwkowski, D. Coombs, D. Baly, F. Kabbinavar and D. Slamon, Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers, Oncogene 18 (1999), 2241-2251.
104. M.D. Pegram, A. Lipton, D.F. Hayes, B.L. Weber, J.M. Baselga, D. Tripathy, D. Baly, S.A. Baughman, T. Twaddell, J.A. Glaspy and D.J. Slamon, Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment, J Clin Oncol 16 (1998), 2659-2671.
105. Y. Tokuda, T. Watanabe, Y. Omuro, M. Ando, N. Katsuma-ta, A. Okumura, M. Ohta, H. Fujii, Y. Sasaki, T. Niwa and T. Tajima, Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer, Br J Cancer 81 (1999), 1419-1425.
106. H.J. Stemmler, M. Schmitt, A. Willems, H. Bernhard, N. Harbeck and V. Heinemann, Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier, Anticancer Drugs 18 (2007), 23-28.
107. D.N. Waterhouse, T. Denyssevych, N. Hudon, S. Chia, K.A. Gelmon and M.B. Bally, Trastuzumab and liposomal Dox-orubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels, Pharm Res 22 (2005), 915-922.
108. A.B. Gottlieb, K.D. Cooper, T.S. McCormick, E. Toichi, D.E. Everitt, B. Frederick, Y. Zhu, C.E. Pendley, M.A. Graham and M.A. Mascelli, A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis, Curr Med Res Opin 23 (2007), 1081-1092.
109. L.H. Kasper, D. Everitt, T.P. Leist, K.A. Ryan, M.A. Mas-celli, K. Johnson, A. Raychaudhuri and T. Vollmer, A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis, Curr Med Res Opin 22 (2006), 1671-1678.
110. C.L. Kauffman, N. Aria, E. Toichi, T.S. McCormick, K.D. Cooper, A.B. Gottlieb, D.E. Everitt, B. Frederick, Y. Zhu, M.A. Graham, C.E. Pendley and M.A. Mascelli, A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis, J Invest Dermatol 123 (2004), 1037-1044.
111. K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, N. Yeilding, C. Guzzo, M.C. Hsu, Y. Wang, S. Li, L.T. Dooley and K. Reich, Efficacy and safety of ustekinum-ab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), Lancet 371 (2008), 1675-1684. (Pubitemid 351671884)
112. B.M. Segal, C.S. Constantinescu, A. Raychaudhuri, L. Kim, R. Fidelus-Gort and L.H. Kasper, Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinum-ab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study, Lancet Neurol 7 (2008), 796-804.
113. Y. Zhu, C. Hu, M. Lu, S. Liao, J.C. Marini, J. Yohrling, N. Yeilding, H.M. Davis and H. Zhou, Population pharmacoki-netic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis, J Clin Pharmacol 49 (2009), 162-175.
114. K. Scheidhauer, I. Wolf, H.J. Baumgartl, C. Von Schilling, B. Schmidt, G. Reidel, C. Peschel and M. Schwaiger, Biodis-tribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lym-phoma, Eur J Nucl Med Mol Imaging 29 (2002), 1276-1282.
115. M. Dietlein, H. Pels, H. Schulz, O. Staak, P. Borchmann, K. Schomacker, T. Fischer, W. Eschner, v. S. Pogge, H. Schicha, A. Engert and R. Schnell, Imaging of central nervous system lymphomas with iodine-123 labeled rituximab, Eur J Haematol 74 (2005), 348-352.
116. G.A. Wiseman, B.R. Leigh, W.D. Erwin, R.B. Sparks, D.A. Podoloff, R.J. Schilder, N.L. Bartlett, S.M. Spies, A.J. Grillo-Lopez, T.E. Witzig and C.A. White, Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia, Cancer Biother Radio-pharm 18 (2003), 165-178.
117. E. Cooney-Qualter, M. Krailo, A. Angiolillo, R.A. Fawwaz, G. Wiseman, L. Harrison, V. Kohl, P.C. Adamson, J. Ayello, V.C. vande, S.L. Perkins and M.S. Cairo, A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lym-phoma: a Children's Oncology Group study, Clin Cancer Res 13 (2007), 5652s-5660s. (Pubitemid 47510400)
118. G.A. Wiseman, C.A. White, R.B. Sparks, W.D. Erwin, D.A. Podoloff, D. Lamonica, N.L. Bartlett, J.A. Parker, W.L. Dunn, S.M. Spies, R. Belanger, T.E. Witzig and B.R. Leigh, Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin ra-dioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, Crit Rev Oncol Hematol 39 (2001), 181-194.
119. G.A. Wiseman, E. Kornmehl, B. Leigh, W.D. Erwin, D.A. Podoloff, S. Spies, R.B. Sparks, M.G. Stabin, T. Witzig and C.A. White, Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials, J Nucl Med 44 (2003), 465-474.
120. M. Cremonesi, M. Ferrari, C.M. Grana, A. Vanazzi, M. Stabin, M. Bartolomei, S. Papi, G. Prisco, P.F. Ferrucci, G. Martinelli and G. Paganelli, High-dose radioimmunothera-py with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment, J Nucl Med 48 (2007), 1871-1879.
121. T. Watanabe, S. Terui, K. Itoh, T. Terauchi, T. Igarashi, N. Usubuchi, M. Nakata, S. Nawano, N. Sekiguchi, S. Kusumo-to, K. Tanimoto, Y. Kobayashi, K. Endo, T. Seriu, M. Hayashi and K. Tobinai, Phase I study of radioimmunothera-py with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma, Cancer Sci 96 (2005), 903-910.
122. M. Dubois, F. Fenaille, G. Clement, M. Lechmann, J.C. Tabet, E. Ezan and F. Becher, Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum, Anal Chem 80 (2008), 1737-1745.
123. C. Hagman, D. Ricke, S. Ewert, S. Bek, R. Falchetto and F. Bitsch, Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrom-etry, Anal Chem 80 (2008), 1290-1296.
124. O. Heudi, S. Barteau, D. Zimmer, J. Schmidt, K. Bill, N. Lehmann, C. Bauer and O. Kretz, Towards absolute quantifi-cation of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry, Anal Chem 80 (2008), 4200-4207.
125. Z. Yang, M. Hayes, X. Fang, M.P. Daley, S. Ettenberg and F.L. Tse, LC-MS/MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2D-solid-phase extraction cleanup, Anal Chem 79 (2007), 9294-9301.
126. J.W. Findlay, Some important considerations for validation of ligand-binding assays, J Chromatogr B Analyt Technol Biomed Life Sci 877 (2009), 2191-2197.
127. C.W. Damen, E.J. Derissen, J.H. Schellens, H. Rosing and J.H. Beijnen, The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity isolation and purification from human serum, J Pharm Biomed Anal In press (2009), doi:10.1016/j.jpba.2009.04.031.
128. L.J. Kricka, Human anti-animal antibody interferences in immunological assays, Clin Chem 45 (1999), 942-956.
129. T. Elter, J. Kilp, P. Borchmann, H. Schulz, M. Hallek and A. Engert, Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia, Haematologica 94 (2009), 150-152.
130. G. Hale, P. Rebello, L.R. Brettman, C. Fegan, B. Kennedy, E. Kimby, M. Leach, J. Lundin, H. Mellstedt, P. Moreton, A.C. Rawstron, H. Waldmann, A. Osterborg and P. Hillmen, Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration, Blood 104 (2004), 948-955.
131. D.R. Mould, A. Baumann, J. Kuhlmann, M.J. Keating, S. Weitman, P. Hillmen, L.R. Brettman, S. Reif and P.L. Bonate, Population pharmacokinetics- pharmacodynamics of alem-tuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response, Br J Clin Phar-macol 64 (2007), 278-291.
132. K. Oshima, Y. Kanda, F. Nakahara, E. Shoda, T. Suzuki, Y. Imai, T. Watanabe, T. Asai, K. Izutsu, S. Ogawa, T. Motoku-ra, S. Chiba and M. Kurokawa, Pharmacokinetics of alem-tuzumab after haploidentical HLA-mismatched hematopoi-etic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies, Am J Hematol 81 (2006), 875-879.
133. P. Rebello, K. Cwynarski, M. Varughese, A. Eades, J.F. Ap-perley and G. Hale, Pharmacokinetics of CAMPATH-1H in BMT patients, Cytotherapy 3 (2001), 261-267.
134. T. Elter, I. Molnar, J. Kuhlmann, M. Hallek and C. Wendt-ner, Pharmacokinetics of alemtuzumab and the relevance in clinical practice, Leuk Lymphoma 49 (2008), 2256-2262.
135. J.M. Kovarik, E. Rawlings, P. Sweny, O. Fernando, R. Moore, P.J. Griffin, P. Fauchald, D. Albrechtsen, G. Sodal, K. Nordal and P.L. Amlot, Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients, Transpl Int 9(Suppl 1) (1996), S32-S33.
136. J.M. Kovarik, G. Offner, M. Broyer, P. Niaudet, C. Loirat, M. Mentser, J. Lemire, J.F. Crocker, P. Cochat, G. Clark, C. Gerbeau, L. Chodoff, A. Korn and M. Hall, A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations, Transplantation 74 (2002), 966-971.
137. J.M. Kovarik, B. Nashan, P. Neuhaus, P.A. Clavien, C. Ger-beau, M.L. Hall and A. Korn, A population pharmacoki-netic screen to identify demographic-clinical covariates of basiliximab in liver transplantation, Clin Pharmacol Ther 69 (2001), 201-209.
138. J.M. Kovarik, M.D. Pescovitz, H.W. Sollinger, B. Kaplan, C. Legendre, K. Salmela, B.K. Book, C. Gerbeau, D. Girault and K. Somberg, Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients, Clin Transplant 15 (2001), 123-130.
139. J.M. Kovarik, B.D. Kahan, P.R. Rajagopalan, W. Bennett, L.L. Mulloy, C. Gerbeau and M.L. Hall, Population phar-macokinetics and exposure-response relationships for basil-iximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group, Transplantation 68 (1999), 1288-1294.
140. J.M. Kovarik, R. Moore, P. Wolf, D. Abendroth, D. Lands-berg, J.P. Soulillou, C. Gerbeau and A.G. Schmidt, Screening for basiliximab exposure-response relationships in renal allotransplantation, Clin Transplant 13 (1999), 32-38.
141. J.M. Kovarik, B.G. Gridelli, S. Martin, B. Rodeck, M. Melter, S.P. Dunn, R.M. Merion, A.G. Tzakis, E. Alonso, J. Bu-cuvalas, H. Sharp, C. Gerbeau, L. Chodoff, A. Korn and M. Hall, Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm, Pediatr Transplant 6 (2002), 224-230.
142. M.R. Mehra, M.J. Zucker, L. Wagoner, R. Michler, J. Boehmer, J. Kovarik and A. Vasquez, A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation, J Heart Lung Transplant 24 (2005), 1297-1304.
143. B. Hocker, J.M. Kovarik, V. Daniel, G. Opelz, H. Fehren-bach, M. Holder, B. Hoppe, P. Hoyer, T.C. Jungraithmayr, S. Kopf-Shakib, G.F. Laube, D.E. Muller-Wiefel, G. Offner, C. Plank, M. Schroder, L.T. Weber, L.B. Zimmerhackl and B. Tonshoff, Pharmacokinetics and immunodynamics of basil-iximab in pediatric renal transplant recipients on mycopheno-late mofetil comedication, Transplantation 86 (2008), 1234-1240.
144. J. Gaudreault, V. Shiu, A. Bricarello, B.J. Christian, C.L. Zuch and B. Mounho, Concomitant administration of beva-cizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics, Int J Toxicol 24 (2005), 357-363.
145. Y.S. Lin, C. Nguyen, J.L. Mendoza, E. Escandon, D. Fei, Y.G. Meng and N.B. Modi, Preclinical pharmacokinetics, inter-species scaling, and tissue distribution of a humanized mon-oclonal antibody against vascular endothelial growth factor, J Pharmacol Exp Ther 288 (1999), 371-378.
146. J.L. Glade Bender, P.C. Adamson, J.M. Reid, L. Xu, S. Baruchel, Y. Shaked, R.S. Kerbel, E.M. Cooney-Qualter, D. Stempak, H.X. Chen, M.D. Nelson, M.D. Krailo, A.M. In-gle, S.M. Blaney, J.J. Kandel and D.J. Yamashiro, Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study, J Clin Oncol 26 (2008), 399-405.
147. R.S. Herbst, D.H. Johnson, E. Mininberg, D.P. Carbone, T. Henderson, E.S. Kim, G. Blumenschein, Jr., J.J. Lee, D.D. Liu, M.T. Truong, W.K. Hong, H. Tran, A. Tsao, D. Xie, D.A. Ramies, R. Mass, S. Seshagiri, D.A. Eberhard, S.K. Kelley and A. Sandler, Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizum-ab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer, J Clin Oncol 23 (2005), 2544-2555.
148. K.N. Ganjoo, C.S. An, M.J. Robertson, L.I. Gordon, J.A. Sen, J. Weisenbach, S. Li, E.A. Weller, A. Orazi and S.J. Horning, Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomark-er and pharmacokinetic analysis, Leuk Lymphoma 47 (2006), 998-1005.
149. L. Xu, C.L. Zuch, Y.S. Lin, N.B. Modi and B.L. Lum, Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys, Cancer Chemother Pharmacol 61 (2008), 607-614.
150. T.U. Krohne, N. Eter, F.G. Holz and C.H. Meyer, Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans, Am J Ophthalmol 146 (2008), 508-512.
151. E. Dib, M. Maia, I.M. Longo-Maugeri, M.C. Martins, J.S. Mussalem, C.C. Squaiella, F.M. Penha, O. Magalhaes, Jr., E.B. Rodrigues and M.E. Farah, Subretinal bevacizumab detection after intravitreous injection in rabbits, Invest Oph-thalmol Vis Sci 49 (2008), 1097-1100.
152. J. Thariat, N. Azzopardi, F. Peyrade, V. Launay-Vacher, J. Santini, T. Lecomte, M.C. Etienne-Grimaldi, G. Paintaud and G. Milano, Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis, J Clin Oncol 26 (2008), 4223-4225.
153. P.M. Fracasso, H. Burris, III, M.A. Arquette, R. Govindan, F. Gao, L.P. Wright, S.A. Goodner, F.A. Greco, S.F. Jones, N. Willcut, C. Chodkiewicz, A. Pathak, G.M. Springett, G.R. Simon, D.M. Sullivan, R. Marcelpoil, S.D. Mayfield, D. Mau-ro and C.R. Garrett, A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing, Clin Cancer Res 13 (2007), 986-993.
154. A.R. Tan, D.F. Moore, M. Hidalgo, J.H. Doroshow, E.A. Poplin, S. Goodin, D. Mauro and E.H. Rubin, Pharmacoki-netics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors, Clin Cancer Res 12 (2006), 6517-6522.
155. A.X. Zhu, K. Stuart, L.S. Blaszkowsky, A. Muzikansky, D.P. Reitberg, J.W. Clark, P.C. Enzinger, P. Bhargava, J.A. Mey-erhardt, K. Horgan, C.S. Fuchs and D.P. Ryan, Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma, Cancer 110 (2007), 581-589.
156. H.J. Lenz, E. Van Cutsem, S. Khambata-Ford, R.J. Mayer, P. Gold, P. Stella, B. Mirtsching, A.L. Cohn, A.W. Pippas, N. Azarnia, Z. Tsuchihashi, D.J. Mauro and E.K. Rowinsky, Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines, J Clin Oncol 24 (2006), 4914-4921.
157. C. Delbaldo, J.Y. Pierga, V. Dieras, S. Faivre, V. Laurence, J.C. Vedovato, M. Bonnay, M. Mueser, A. Nolting, A. Ko-var and E. Raymond, Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma, Eur J Cancer 41 (2005), 1739-1745.
158. K. Shirao, T. Yoshino, N. Boku, K. Kato, T. Hamaguchi, H. Yasui, N. Yamamoto, Y. Tanigawara, A. Nolting and S. Yoshino, A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors, Cancer Chemother Pharmacol 65 (2009), 557-564.
159. N.L. Dirks, A. Nolting, A. Kovar and B. Meibohm, Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck, J Clin Pharmacol 48 (2008), 267-278.
160. H.B. Koon, P. Severy, D.S. Hagg, K. Butler, T. Hill, A.G. Jones, T.A. Waldmann and R.P. Junghans, Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing, Leuk Res 30 (2006), 190-203.
161. S. Vermeire, M. Noman, G. Van Assche, F. Baert, G. D'Haens and P. Rutgeerts, Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease, Gut 56 (2007), 1226-1231.
162. K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M.C. Kapetanovic and T. Saxne, Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab, Arthritis Rheum 54 (2006), 3782-3789.
163. M. Svenson, P. Geborek, T. Saxne and K. Bendtzen, Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies, Rheumatology (Oxford) 46 (2007), 1828-1834.
164. G.J. Wolbink, M. Vis, W. Lems, A.E. Voskuyl, E. de Groot, M.T. Nurmohamed, S. Stapel, P.P. Tak, L. Aarden and B. Dijkmans, Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis, Arthritis Rheum 54 (2006), 711-715.
165. S. Mori, A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy, Mod Rheumatol 17 (2007), 83-91.
166. A.B. Gottlieb, S. Masud, R. Ramamurthi, A. Abdulghani, P. Romano, U. Chaudhari, L.T. Dooley, A.A. Fasanmade and C.L. Wagner, Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris, J Am Acad Dermatol 48 (2003), 68-75.
167. J.C. Burns, B.M. Best, A. Mejias, L. Mahony, D.E. Fixler, H.S. Jafri, M.E. Melish, M.A. Jackson, B.I. Asmar, D.J. Lang, J.D. Connor, E V. Capparelli, M.L. Keen, K. Mamun, G.F. Keenan and O. Ramilo, Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease, J Pedi-atr 153 (2008), 833-838.
168. E.W. St Clair, C.L. Wagner, A.A. Fasanmade, B. Wang, T. Schaible, A. Kavanaugh and E.C. Keystone, The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a mul-ticenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum 46 (2002), 1451-1459.
169. K. Nishimura, N. Wakimoto, J. Sasahara, N. Nakamura, C. Yanagisawa, J. Nishino, H. Tomiyama and T. Matsushita, No changes in infliximab levels in blood stored for preoperative autologous blood donation, Mod Rheumatol 18 (2008), 29-33.
170. M.U. Rahman, I. Strusberg, P. Geusens, A. Berman, D. Yocum, D. Baker, C. Wagner, J. Han and R. Westhovens, Double-blinded infliximab dose escalation in patients with rheumatoid arthritis, Ann Rheum Dis 66 (2007), 1233-1238.
171. J.R. Rojas, R.P. Taylor, M.R. Cunningham, T.J. Rutkoski, J. Vennarini, H. Jang, M.A. Graham, K. Geboes, S.D. Rous-selle and C.L. Wagner, Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys, J Pharmacol Exp Ther 313 (2005), 578-585.
172. A. Jatoi, J.R. Jett, J. Sloan, P. Novotny, J. Ford, U. Prabhakar and C.L. Loprinzi, A pilot study on safety and pharmacoki-netics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients, Support Care Cancer 12 (2004), 859-863.
173. S. Ohno, S. Nakamura, S. Hori, M. Shimakawa, H. Kawashima, M. Mochizuki, S. Sugita, S. Ueno, K. Yoshizaki and G. Inaba, Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis, J Rheumatol 31 (2004), 1362-1368.
174. R. Maini, E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, M. Feldmann and P. Lipsky, Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group, Lancet 354 (1999), 1932-1939.
175. R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Furst, M.H. Weisman, E.W. St Clair, G.F. Keenan, H.D. van der, P.A. Marsters and P.E. Lipsky, Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate, Arthritis Rheum 50 (2004), 1051-1065.
176. F. Cornillie, D. Shealy, G. D'Haens, K. Geboes, G. Van Assche, J. Ceuppens, C. Wagner, T. Schaible, S.E. Plevy, S.R. Targan and P. Rutgeerts, Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease, Aliment Pharmacol Ther 15 (2001), 463-473.
177. P. Rutgeerts, G. D'Haens, S. Targan, E. Vasiliauskas, S.B. Hanauer, D.H. Present, L. Mayer, R.A. Van Hogezand, T. Braakman, K.L. DeWoody, T.F. Schaible and S.J. Van De-venter, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease, Gastroenterology 117 (1999), 761-769.
178. E.A. Maser, R. Villela, M.S. Silverberg and G.R. Greenberg, Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease, Clin Gastroenterol Hepatol 4 (2006), 1248-1254.
179. G. Goldstein, D.J. Norman, K.R. Henell and I.L. Smith, Phar-macokinetic study of orthoclone OKT3 serum levels during treatment of acute renal allograft rejection, Transplantation 46 (1988), 587-589.
180. G. Goldstein, A.J. Fuccello, D.J. Norman, C.F. Shield, III, R.B. Colvin and A.B. Cosimi, OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3, Transplantation 42 (1986), 507-511.
181. D. Abramowicz, M. Goldman, O. Mat, G. Estermans, A. Crusiaux, J.L. Vanherweghem, L. De Pauw, P. Kinnaert and P. Vereerstraeten, OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients, Transpl Int 7 (1994), 258-263.
182. S.V. McDiarmid, M. Millis, G. Terashita, M.E. Ament, R. Busuttil and P. Terasaki, Low serum OKT3 levels correlate with failure to prevent rejection in orthotopic liver transplant patients, Transplant Proc 22 (1990), 1774-1776.
183. T.J. Schroeder, A.T. Michael, M.R. First, S. Hariharan, G. Bhat, D.W. Hanto, F.C. Ryckman and W.F. Balistreri, Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen, and anti-OKT3 antibody status, Ther Drug Monit 16 (1994), 361-367.
184. T.J. Schroeder, M.R. First, P.E. Hurtubise, D.J. Marmer, D.M. Martin, M.E. Mansour and D.B. Melvin, Immunologic monitoring with Orthoclone OKT3 therapy, J Heart Transplant 8 (1989), 371-380.
185. M. Toyoda, K. Galfayan, K. Wachs, L. Czer and S.C. Jordan, Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients, Clin Transplant 9 (1995), 472-480.
186. M.B. Regazzi, I. Iacona, M.A. Avanzini, L. Arcaini, G. Mer-lini, V. Perfetti, F. Zaja, M. Montagna, E. Morra and M. Lazzarino, Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings, Ther Drug Monit 27 (2005), 785-792.
187. A.P. Jillella, P.M. Dainer, A.M. Kallab and C. Ustun, Treatment of a patient with end-stage renal disease with Ritux-imab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis, Am J Hematol 71 (2002), 219-222.
188. M.S. Cragg, M.B. Bayne, A.L. Tutt, R.R. French, S. Beers, M.J. Glennie and T.M. Illidge, A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells, Blood 104 (2004), 2540-2542.
189. R. Seror, C. Sordet, L. Guillevin, E. Hachulla, C. Masson, M. Ittah, S. Candon, G. Le, V, A. Aouba, J. Sibilia, J.E. Gotten-berg and X. Mariette, Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome, Ann Rheum Dis 66 (2007), 351-357.
190. J.C. Byrd, T. Murphy, R.S. Howard, M.S. Lucas, A. Goodrich, K. Park, M. Pearson, J.K. Waselenko, G. Ling, M.R. Grever, A.J. Grillo-Lopez, J. Rosenberg, L. Kunkel and I.W. Flinn, Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lympho-cytic lymphoma demonstrates clinical activity and acceptable toxicity, J Clin Oncol 19 (2001), 2153-2164.
191. T. Igarashi, Y. Kobayashi, M. Ogura, T. Kinoshita, T. Ohtsu, Y. Sasaki, Y. Morishima, T. Murate, M. Kasai, N. Uike, M. Taniwaki, Y. Kano, K. Ohnishi, Y. Matsuno, S. Nakamura, S. Mori, Y. Ohashi and K. Tobinai, Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study, Ann Oncol 13 (2002), 928-943.
192. D.G. Maloney, T.M. Liles, D.K. Czerwinski, C. Waldichuk, J. Rosenberg, A. Grillo-Lopez and R. Levy, Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma, Blood 84 (1994), 2457-2466.
193. K. Tobinai, Y. Kobayashi, M. Narabayashi, M. Ogura, Y. Kagami, Y. Morishima, T. Ohtsu, T. Igarashi, Y. Sasaki, T. Kinoshita and T. Murate, Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group, Ann Oncol 9 (1998), 527-534.
194. C.A. Vieira, A. Agarwal, B.K. Book, R.A. Sidner, C.M. Bear-den, H.M. Gebel, A.L. Roggero, N.S. Fineberg, T. Taber, M.A. Kraus and M.D. Pescovitz, Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics, Transplantation 77 (2004), 542-548.
195. L.D. Piro, C.A. White, A.J. Grillo-Lopez, N. Janakiraman, A. Saven, T.M. Beck, C. Varns, S. Shuey, M. Czuczman, J.W. Lynch, J.E. Kolitz and V. Jain, Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma, Ann Oncol 10 (1999), 655-661.
196. T. Maeda, Y. Yamada, M. Tawara, R. Yamasaki, Y. Yakata, C. Tsutsumi, Y. Onimaru, S. Kamihira and M. Tomonaga, Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody, Int J Hematol 74 (2001), 70-75.
197. K. Tobinai, T. Igarashi, K. Itoh, Y. Kobayashi, M. Taniwaki, M. Ogura, T. Kinoshita, T. Hotta, K. Aikawa, K. Tsushita, A. Hiraoka, Y. Matsuno, S. Nakamura, S. Mori and Y. Ohashi, Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma, Ann Oncol 15 (2004), 821-830.
198. K. Tobinai, Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan, Cancer Chemother Pharma-col 48 Suppl 1 (2001), S85-S90.
199. P. McLaughlin, F.B. Hagemeister and A.J. Grillo-Lopez, Rit-uximab in indolent lymphoma: the single-agent pivotal trial, Semin Oncol 26 (1999), 79-87.
200. M. Ogura, Y. Morishima, Y. Kagami, T. Watanabe, K. Itoh, T. Igarashi, T. Hotta, T. Kinoshita, Y. Ohashi, S. Mori, T. Terauchi and K. Tobinai, Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma, Cancer Sci 97 (2006), 305-312.
201. J. Baselga, X. Carbonell, N.J. Castaneda-Soto, M. Clemens, M. Green, V. Harvey, S. Morales, C. Barton and P. Ghahra-mani, Phase II study of efficacy, safety, and pharmacokinet-ics of trastuzumab monotherapy administered on a 3-weekly schedule, J Clin Oncol 23 (2005), 2162-2171.
202. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, L. Dantis, N.T. Sklarin, A.D. Seidman, C.A. Hudis, J. Moore, P.P. Rosen, T. Twaddell, I.C. Henderson and L. Norton, Phase II study of weekly intravenous trastuzumab (Her-ceptin) in patients with HER2/neu-overexpressing metastatic breast cancer, Semin Oncol 26 (1999), 78-83. (Pubitemid 29411436)
203. M.A. Bookman, K.M. Darcy, D. Clarke-Pearson, R.A. Boothby and I.R. Horowitz, Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group, J Clin Oncol 21 (2003), 283-290.
204. R. Bruno, C.B. Washington, J.F. Lu, G. Lieberman, L. Banken and P. Klein, Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer, Cancer Chemother Pharmacol 56 (2005), 361-369.
205. M.A. Cobleigh, C.L. Vogel, D. Tripathy, N.J. Robert, S. Scholl, L. Fehrenbacher, J.M. Wolter, V. Paton, S. Shak, G. Lieberman and D.J. Slamon, Multinational study of the ef-ficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastat-ic breast cancer that has progressed after chemotherapy for metastatic disease, J Clin Oncol 17 (1999), 2639-2648.
206. B. Leyland-Jones, K. Gelmon, J.P. Ayoub, A. Arnold, S. Ver-ma, R. Dias and P. Ghahramani, Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel, J Clin Oncol 21 (2003), 3965-3971.
207. R.G. Zinner, B.S. Glisson, F.V. Fossella, K.M. Pisters, M.S. Kies, P.M. Lee, E. Massarelli, B. Sabloff, H.A. Fritsche, Jr., J.Y. Ro, N.G. Ordonez, H.T. Tran, Y. Yang, T.L. Smith, R.D. Mass and R.S. Herbst, Trastuzumab in combination with cis-platin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease, Lung Cancer 44 (2004), 99-110.
208. G. Bianchi, J. Albanell, W. Eiermann, G. Vitali, D. Borquez, L. Vigano, R. Molina, G. Raab, A. Locatelli, B. Vanhauwere, L. Gianni and J. Baselga, Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer, Clin Cancer Res 9 (2003), 5944-5951.